MedPath

Study of XL999 in Adults With Solid Tumors

Phase 1
Completed
Conditions
Cancer
Registration Number
NCT00104117
Lead Sponsor
Symphony Evolution, Inc.
Brief Summary

The purpose of this study is to assess the safety and tolerability of XL999 in adults with advanced solid tumors.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
52
Inclusion Criteria
  • Advanced solid tumor
  • Cancer that has progressed on currently available therapies
  • Life expectancy of >3 months
  • Adequate bone marrow, liver, and kidney function
  • Willing to use accepted method of contraception during the course of the study
  • Negative pregnancy test (females)
  • Written informed consent
Exclusion Criteria
  • Chemotherapy within 4-6 weeks of the start of treatment (depending on the therapy)
  • Radiotherapy within 4 weeks of the start of treatment
  • Subjects with known brain metastasis
  • Uncontrolled medical disorder such as infection or cardiovascular disease
  • Subjects known to be HIV positive
  • Pregnant or breastfeeding women

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
To determine the maximum tolerated dose (MTD) and to assess the safety and tolerability of XL999 administered as a single 4-hour intravenous (IV) infusion in subjects with solid tumorsInclusion until 30 days post last treatment
Secondary Outcome Measures
NameTimeMethod
To evaluate plasma pharmacokinetics (PK) and estimate renal elimination of XL999 administered as a single 4-hour IV infusion in subjects with solid tumorsVarious timepoints from pre-dosing until 48 hours post dose.
To evaluate the PK of XL999 administered at a fixed weekly dose of 200 mg.At various timepoints from pre-dosing until 48 hours post dosing

Trial Locations

Locations (2)

Case Western Reserve University, Univserzity Hospitals of Cleveland

🇺🇸

Cleveland, Ohio, United States

Cancer Therapy and Research Center, Institute for Drug Development

🇺🇸

San Antonio, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath